| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC3878 |
| Trial ID | NCT06413498 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CART-ddBCMA|Anitocabtagene Autoleucel |
| Phase | Phase3 |
| Recruitment status | Not Recruiting |
| Title | A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma |
| Year | 2024 |
| Country | United States |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KT-US-679-0788|2024-511188-26 |
| Cohort 1 | |||||||||||
|
|||||||||||